Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Therapeutic Potential and Challenges of Targeting Receptor Tyrosine Kinase ROR1 with Monoclonal Antibodies in B-Cell Malignancies

15 Jun 2011

Abstract excerpt

BACKGROUND: Based on its selective cell surface expression in chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL), receptor tyrosine kinase ROR1 has recently emerged as a promising target for therapeutic monoclonal antibodies (mAbs). To further assess the suitability of ROR1 for targeted therapy of CLL and MCL, a panel of mAbs was generated and its therapeutic utility was investigated. METHODOLOGY...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to HER2/EGFR in Cancer Research
Share to Monoclonal and Polyclonal Antibodies Research
Share to Toxin Mechanisms and Immunotoxins

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 21698301
DOI: 10.1371/journal.pone.0021018

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Therapeutic Potential and Challenges of Targeting Receptor Tyrosine Kinase ROR1 with Monoclonal Antibodies in B-Cell MalignanciesPMID 21698301Read ↗

Potent and selective antitumor activity of a T cell-engaging bispecific antibody targeting a membrane-proximal epitope of ROR1Semantic proximity Read ↗

Characterization of lymphoma models for the surface ROR1 expressionSemantic proximity Read ↗

Targeting ROR1 identifies new treatment strategies in hematological cancersSemantic proximity Read ↗

Novel humanized monoclonal antibodies against ROR1 for cancer therapySemantic proximity Read ↗

ROR1: an orphan becomes apparentSemantic proximity Read ↗

Affinity maturation, humanization, and co-crystallization of a rabbit anti-human ROR2 monoclonal antibody for therapeutic applicationsSemantic proximity Read ↗

Cutting Edge: ROR1/CD19 Receptor Complex Promotes Growth of Mantle Cell Lymphoma Cells Independently of the B Cell Receptor–BTK Signaling PathwaySemantic proximity Read ↗

The arming of NK cells with Fc-engineered rituximab confers them specificity against CD20-expressing cellsSemantic proximity Read ↗

Targeted Therapy in Chronic Lymphocytic LeukemiaSemantic proximity Read ↗

Restricted Cell Surface Expression of Receptor Tyrosine Kinase ROR1 in Pediatric B-Lineage Acute Lymphoblastic Leukemia Suggests Targetability with Therapeutic Monoclonal AntibodiesSemantic proximity Read ↗

Antisera induced by infusions of autologous Ad-CD154-leukemia B cells identify ROR1 as an oncofetal antigen and receptor for Wnt5aSemantic proximity Read ↗

Reimagining antibody-dependent cellular cytotoxicity in cancer: the potential of natural killer cell engagersSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.